Business Analysts Set Denali Therapeutics Price Target at $33.50 Denali Therapeutics Inc. (NASDAQ:DNLI) has received an average rating of “Buy” from a group of seventeen analysts currently covering the company, according to MarketBeat.... Editorial9 hours ago